Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Analysis of Emerging Data for the Treatment of Amyloidosis
Author(s): Julian Gillmore , Margot K Davis Added: 8 months ago
This programme, featuring Prof Julian Gillmore (University College London, London, UK) and Dr Margot Davis (Vancouver General Hospital, Vancouver, CA) offers an in-depth exploration of ATTR amyloidosis, highlighting the value of observational research in understanding disease presentation, treatment patterns, and outcomes. Viewers will learn about the pathophysiology and spectrum of the condition… View more

Heart Failure
Ep 143: GDMT Optimisation: Mitigating SCD Risk and Addressing Women’s Cardiac Health
Added: 7 months ago
In this episode of Parallax, Dr Ankur Kalra speaks with Dr Benjamin A D’Souza, Associate Professor of Medicine at the University of Pennsylvania and Section Chief of Cardiac Electrophysiology at Presbyterian Medical Center. Together, they explore the challenges of mitigating sudden cardiac death and the evolving role of guideline-directed medical therapy in optimising patient outcomes.Dr D’Souza… View more

Heart Failure
Start date: Feb 25, 2025 End date: Feb 26, 2025
Due to the recent success of New Horizons in Amyloidosis, Radcliffe Cardiology are excited to introduce a new 2-day event ‘New Horizons in Cardiomyopathy’ (NHC) in February 2025.The event, hosted on Radcliffe Cardiology, will be streamed on Tuesday 25 February - Wednesday 26February 2025. It promises an interactive and informative experience, updating professionals on cardiac amyloidosis and… View more

Heart Failure
Portrait image of Stavros Stavrakis
Research Area(s) / Expertise:

Atrial Fibrillation

 Job title: Associate Professor of Medicine; Laureate Chair in Molecular Medicine; Vice Chief, Cardiovascular Section
Dr Stavrakis is a clinical cardiac electrophysiologist and Associate Professor of Medicine at the University of Oklahoma Health Sciences Center. He is also the Director of Cardiovascular Research at the University of Oklahoma. Dr Stavrakis’ research has focused on autonomic modulation for the treatment of arrhythmias and other cardiovascular diseases, in both animal models and humans. The… View more
Abhishek Joshi
Job title: Cardiac Imaging Fellow
Personal History Dr Abhishek Joshi is a Cardiologist based in London. He is a Cardiology Registrar at Barts Heart Centre and a Clinical Research Training Fellow at the British Heart Foundation. He holds a PhD in Cardiovascular Science from King’s College London. In his spare time, Dr Joshi plays the bass guitar and enjoys video games.2 Academic History In 2003, he obtained his BA… View more
Angelo Auricchio
Research Area(s) / Expertise:

Electrophysiology & Arrhythmia

 Job title: Director of the Clinical Electrophysiology Unit
Personal History Prof Angelo Auricchio was born in 1960 in Terzigno, southern Italy. He speaks Italian, English and German.4 As a teenager, he was fascinated by mechanics and electricity. “In my view, the heart and the circulatory system is a wonderful piece of machinery that is driven by an electrical system that is both uncomplicated and powerful,” he says.5 He enjoys photography,… View more
Research Area(s) / Expertise:
Dr Saba received his MB, MCh from Cairo University's Faculty of Medicine, Egypt in 1994. He then went on to complete a house officer post at Cairo University Hospitals in 1995, completed a fellowship program and MSc degree in cardiovascular medicine from 1996 to 1999 before taking up a post as lecturer in cardiovascular medicine at Cairo University in November 1999. Dr Saba then completed an… View more
Updates on Icosapent Ethyl and Cardiometabolic Risk
Author(s): Philippe Gabriel Steg , Matthew J Budoff Added: 1 year ago
Filmed onsite at ACC 2025, this on-demand series features key insights from Dr Matthew Budoff and Prof Philippe Gabriel Steg to interpret the latest data on icosapent ethyl (IPE), including a new analysis from the REDUCE-IT trial on baseline LDL-C, two new meta-analyses and a retrospective study on plaque progression in patients treated with IPE and a PCSK9 inhibitor.In these concise summaries,… View more

Heart Failure

Prevention & Chronic Conditions
EASD 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk
Author(s): Rahul Aggarwal , Dirk Müller-Wieland Added: 7 months ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type… View more

Heart Failure

Prevention & Chronic Conditions
Novel Therapies in ATTR-CM
Author(s): Michelle Dimza , Georgia Vasilakis , Justin L Grodin Added: 6 months ago

Heart Failure